An Extension Study of JR-141 in Patients With Mucopolysaccharidosis II
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis II
Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety
 of study drug for the treatment of the MPS II.
Inclusion Criteria:

 1. Patients who will have completed clinical trial JR-141-301 and judged by the
 investigator or subinvestigator to be able to participate in the study from safety
 aspects.

 2. Capable of providing written consent by himself, unless the patient is under the age
 of 20 years at the time of informed consent process, or it is not possible to obtain
 consent from the patient himself due to his intellectual disabilities associated with
 MPS II.

 3. In the case of a patient who is under the age of 20 years or from whom it is not
 possible to obtain consent due to his intellectual disabilities associated with MPS
 II, he may be included if written consent can be provided by legal representative;
 however written consent should be obtained from the patient himself too, wherever
 possible.

 Exclusion Criteria:

 1. Judged by the investigator or subinvestigator to be ineligible to participate in the
 study due to receive concomitant therapy which affectseffect the clinical evaluation.

 2. Judged by the investigator or subinvestigator to be ineligible to participate in the
 study due to a history of a serious drug allergy or sensitivity.

 3. Otherwise judged by the investigator or subinvestigator to be ineligible to
 participate in the study.